Indivior Pharmaceuticals, Inc. (INDV) Operating Margin
- Operating margin · 12 months: Value 31.63%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 31.63% | Operating income / revenue. Period ending 2026-06-30. $421.00M ÷ $1.33B × 100 ≈ 31.63% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 421.00M USD | Operating Income (Loss) |
| Revenue | 1.33B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 240.00M USD | Cost of Goods and Services Sold |
| Research and development | (m) | |
| Selling, general and administration | 588.00M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $421.00M | $1.33B | $240.00M | (m) | $588.00M | 31.63% |
| 2026-03-31 | $333.00M | $1.29B | $242.00M | (m) | $625.00M | 25.81% |
| 2025-12-31 | $262.00M | $1.24B | $246.00M | (m) | $634.00M | 21.15% |
| 2025-09-30 | $227.00M | $1.18B | $227.00M | (m) | $620.00M | 19.24% |
| 2025-06-30 | $219.00M | $1.17B | $210.00M | (m) | $607.00M | 18.67% |
| 2025-03-31 | $29.00M | $1.17B | $237.00M | (m) | $601.00M | 2.48% |
| 2024-12-31 | $32.00M | $1.19B | $231.00M | (m) | $618.00M | 2.69% |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-156.00M | $1.09B | $174.00M | (m) | $569.00M | -14.27% |
| 2022-12-31 | $-81.00M | $901.00M | $151.00M | (m) | $469.00M | -8.99% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |